Apoptose und Melanom: Neue therapeutische Zielstrukturen^[*]

Zusammenfassung

Da die bekannten Chemotherapeutika bei Patienten mit metastasiertem malignem Melanom nur stark eingeschränkt wirksam sind, ist es notwendig, neue Ansätze ausfindig zu machen, die sich als therapeutische Zielstrukturen eignen. Wie wir in unseren experimentellen Untersuchungen zeigen konnten, könnte TRAIL eine neue Therapiestrategie beim metastasierten Melanom darstellen, die vielversprechend erscheint.

Abstract

Since most chemotherapeutic agents are less or non-effective in malignant melanoma, there is a need for exploring new targets for influencing growth and metastatic potential of this highly malignant neoplasm. Our experiments on human melanoma cell lines in vitro indicate that TRAIL may be a structure to be used as a therapeutic target, thus influencing apoptosis resistance in melanoma cells.

^* Nach einem Vortrag anlässlich des 11. Jahressymposions der Berliner Stiftung für Dermatologie am 2. Juli 2011, Berlin.

• Literatur

• 1 Fecker LF, Rückert S, Kurbanov BM et al. Efficient melanoma cell killing and reduced melanoma growth in mice by a selective replicating adenovirus armed with tumor necrosis factor-related apoptosis-inducing ligand. Hum Gene Ther 2011; 22: 405-417
• 2 Eberle J, Fecker LF, Hossini AM et al. Apoptosis pathways and oncolytic adenoviral vectors: promising targets and tools to overcome therapy resistance of malignant melanoma. Exp Dermatol 2008; 17: 1-11
• 3 Eberle J, Kurbanov BM, Hossini AM et al. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches. Drug Resist Updat 2007; 10: 218-234
• 4 Kurbanov BM, Fecker LF, Geilen CC et al. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Oncogene 2007; 26: 3364-3377
• 5 Fecker LF, Geilen CC, Tchernev G et al. Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol 2006; 126: 1366-1371
• 6 Kurbanov BM, Geilen CC, Fecker LF et al. Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Invest Dermatol 2005; 125: 1010-1019